Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide Dose-Finding in Type 2 Diabetes
NCT01923181Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2013
- Primary completion
- Dec 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
A Phase 2 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01923181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01923181.